2-deoxyglucose
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 3, 2022 (NCT05314933)
Timeline
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
OCC1OC(O)CC(O)C1O- Mol. weight
- 164.16 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1880349 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06375772 | Phase 2 | Apr 2, 2024 | G.ST Antivirals GmbH, Leiden University |
| NCT05605301 | Phase 2 | Sep 2, 2022 | Epilepsy Foundation, University of Virginia, University of Wisconsin |
| NCT05314933 | Phase 1 | Mar 3, 2022 | G.ST Antivirals GmbH |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| G.ST Antivirals GmbH | For profit | 2 | 2 | 2 | 2022 |
| Epilepsy Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1